Neurosona Signs Business Agreement with Biwave for "Development of Brainwave-Related Solutions"

Neurosona, a company specializing in the development of electronic medicine for brain disease treatment, announced on the 26th that it has signed a business agreement with Biwave to develop brainwave analysis and brain care solutions.

Under this business agreement, both companies will cooperate on technology related to their respective technologies. They also plan to collaborate on joint marketing for their products and services.

Biwave is an AI-based mental health healthcare company that evaluates and diagnoses mental health using biometric signals. Through its flagship service 'Ma-eumgyeol,' it conducts biological mental health assessments and diagnoses using brainwaves and heart rate variability (hereinafter referred to as Macpa).

Neurosona is conducting clinical trials applying the 'Low-Intensity Focused Ultrasound Stimulation System' to patients with various brain diseases such as depression, Alzheimer's, sleep disorders, and stroke. Neurosona's Low-Intensity Focused Ultrasound Stimulation System non-invasively stimulates precise and safe local areas deep within the brain, selectively modulating the behavior of nerve cells. Since it does not require surgical procedures, it has the advantage of reducing side effects such as infections and complications.

Seonil Seo, CEO of Neurosona, said, "We expect great synergy through collaboration with Biwave, which has strong advantages in AI analysis software for brain-related biometric signals," adding, "It will greatly help in making our products more welcomed in the market."

This content was produced with the assistance of AI translation services.